Quadrant Capital Group’s Dyne Therapeutics DYN Stock Holding History

Quadrant Capital Group’s Portfolio DYN Stock Details DYN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$1.22K	Hold	67	–	–	﹤0.01%	2564
2025 Q4	$1.31K	Hold	67	–	–	﹤0.01%	2572
2025 Q3	$848	Buy	+67	New	+$764	﹤0.01%	2570
2025 Q2	–	Sell	-231	Closed	-$2.42K	–	1712
2025 Q1	$2.42K	Hold	231	–	–	﹤0.01%	2481
2024 Q4	$5.44K	Hold	231	–	–	﹤0.01%	2280
2024 Q3	$8.3K	Hold	231	–	–	﹤0.01%	2193
2024 Q2	$8.15K	Hold	231	–	–	﹤0.01%	2180
2024 Q1	$6.56K	Hold	231	–	–	﹤0.01%	2245
2023 Q4	$3.07K	Buy	+231	New	+$2.26K	﹤0.01%	2392

Other funds holding DYN

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

AVLSA

Atlas Venture Life Science Advisors Cambridge, Massachusetts $790M AUM 223.66% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

OAG

Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return

FIS

FCPM III Services Naarden, Netherlands $722M AUM 73.61% 1-Year Est. Return

Quadrant Capital Group's DYN Position: Q1 2026 in Review

Quadrant Capital Group held its Dyne Therapeutics (DYN) position steady in Q1 2026 at 67 shares worth $1.22K. The position accounts for ﹤0.01% of the portfolio, ranked #2564.

Quadrant Capital Group first reported a position in DYN in Q4 2023 and has held it in 9 quarters since. The position peaked at $8.3K in Q3 2024. 227 funds tracked by Wall St. Rank hold DYN as of Q1 2026.

Quadrant Capital Group held 67 shares of Dyne Therapeutics worth $1.22K as of Q1 2026.
Quadrant Capital Group left its Dyne Therapeutics share count unchanged in Q1 2026.
Dyne Therapeutics made up ﹤0.01% of Quadrant Capital Group's portfolio in Q1 2026, its #2564 holding.
Quadrant Capital Group first reported a position in Dyne Therapeutics in Q4 2023 and has held it in 9 quarters since.
Quadrant Capital Group's Dyne Therapeutics position peaked at $8.3K in Q3 2024.
227 funds tracked by Wall St. Rank held Dyne Therapeutics as of Q1 2026.

Based on Quadrant Capital Group's 13F filing for Q1 2026, filed 11 May 2026.